ModernaTX, Inc.
227Patents
227Active
227Granted
61Portfolio score
Filing activity: Mar 9, 2013 → Jan 15, 2025
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9872900B2 | Nucleic acid vaccines | Emerging Cross-Sectional Technologies | 144 | Active |
| US9868691B2 | Compounds and compositions for intracellular delivery of therapeutic agents | Chemistry; Metallurgy | 126 | Active |
| US9597380B2 | Terminally modified RNA | Chemistry; Metallurgy | 125 | Active |
| US10064935B2 | Human cytomegalovirus RNA vaccines | Chemistry; Metallurgy | 112 | Active |
| US9512456B2 | Enzymes and polymerases for the synthesis of RNA | Chemistry; Metallurgy | 104 | Active |
| US10064934B2 | Combination PIV3/hMPV RNA vaccines | Emerging Cross-Sectional Technologies | 95 | Active |
| US10124055B2 | Zika virus RNA vaccines | Emerging Cross-Sectional Technologies | 93 | Active |
| US9533047B2 | Delivery and formulation of engineered nucleic acids | Chemistry; Metallurgy | 87 | Active |
| US10207010B2 | Compositions and methods for delivery of agents | Chemistry; Metallurgy | 86 | Active |
| US10273269B2 | High potency immunogenic zika virus compositions | Emerging Cross-Sectional Technologies | 79 | Active |
| US10465190B1 | In vitro transcription methods and constructs | Chemistry; Metallurgy | 73 | Active |
| US10493143B2 | Sexually transmitted disease vaccines | Emerging Cross-Sectional Technologies | 72 | Active |
| US10449244B2 | Zika RNA vaccines | Emerging Cross-Sectional Technologies | 72 | Active |
| US10286086B2 | Alternative nucleic acid molecules and uses thereof | Chemistry; Metallurgy | 68 | Active |
| US10695419B2 | Human cytomegalovirus vaccine | Emerging Cross-Sectional Technologies | 66 | Active |
| US9572896B2 | In vivo production of proteins | Chemistry; Metallurgy | 65 | Active |
| US10526629B2 | RNA polymerase variants | Chemistry; Metallurgy | 65 | Active |
| US10653767B2 | Zika virus MRNA vaccines | Emerging Cross-Sectional Technologies | 65 | Active |
| US10653712B2 | High purity RNA compositions and methods for preparation thereof | Physics | 63 | Active |
| US10925958B2 | Influenza vaccine | Chemistry; Metallurgy | 59 | Active |
| US9587003B2 | Modified polynucleotides for the production of oncology-related proteins and peptides | Chemistry; Metallurgy | 59 | Active |
| US10385088B2 | Polynucleotide molecules and uses thereof | Chemistry; Metallurgy | 58 | Active |
| US9868692B2 | Compounds and compositions for intracellular delivery of therapeutic agents | Chemistry; Metallurgy | 56 | Active |
| US10022435B2 | Nucleic acid vaccines | Emerging Cross-Sectional Technologies | 53 | Active |
| US11045540B2 | Varicella zoster virus (VZV) vaccine | Chemistry; Metallurgy | 52 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.